整合老年评估与治疗有效性研究:老年癌症患者系统抗癌治疗中的随机对照试验
INTEGERATE 是在澳大利亚三家医院开展的多中心、开放标签、实用性随机对照试验,纳入 154 例 70 岁及以上、计划接受化疗/靶向/免疫治疗的实体瘤或弥漫大 B 细胞淋巴瘤患者,评估将综合老年评估(CGA)整合入肿瘤照护能否改善健康相关生活质量(HRQOL)。
要点
- CGA 整合入肿瘤照护可改善老年癌症患者 24 周 HRQOL,第 18 周差异最明显。
- 总生存无显著组间差异,需权衡生活质量与医疗资源使用获益。
核心结论
- CGA 可改善接受系统抗癌治疗的老年癌症患者的生活质量与照护服务,建议对高危老年患者在开始系统抗癌治疗时考虑常规 CGA 干预。
研究设计与样本
- 多中心、开放标签、实用性、平行组随机对照试验,在澳大利亚三家医院开展,纳入 154 例 70 岁及以上、计划接受化疗/靶向/免疫治疗的实体瘤或弥漫大 B 细胞淋巴瘤患者,1:1 随机分配至整合肿瘤老年照护组(n=76)或常规照护组(n=78)。
主要发现
- 总生存无统计学显著组间差异。
关键数值与推荐
- 主要结局为 24 周 HRQOL,采用 ELFI 评估(评分范围 0-100),在基线、第 12、18、24 周评估,按意向治疗分析。
临床怎么用
- 对 70 岁及以上、计划开始系统抗癌治疗的实体瘤或弥漫大 B 细胞淋巴瘤患者,可考虑将 CGA 整合入肿瘤照护以改善生活质量和减少非计划入院。
局限性
- 研究为开放标签设计,分组未对参与者和临床医生隐藏。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The effectiveness of comprehensive geriatric assessment (CGA) in improving health outcomes in cancer settings is unclear. We evaluated whether CGA can improve health-related quality of life (HRQOL) in older people with cancer who are starting systemic anticancer treatment. METHODS: INTEGERATE is a multicentre, open-label, pragmatic, parallel-group, randomised controlled trial that was done at three hospitals in Australia. Participants aged 70 years and older with solid cancer or diffuse large B-cell lymphoma planned for chemotherapy, targeted therapy, or immunotherapy, were randomly assigned (1:1; using a central computer-generated minimisation algorithm with a random element, balancing treatment intent, cancer type, age, sex, and performance status) to receive CGA integrated into oncology care (integrated oncogeriatric care) or usual care only. Group assignment was not concealed from the participants and clinicians. The primary outcome was HRQOL over 24 weeks, assessed at baseline, week 12, week 18, and week 24, using the Elderly Functional Index (ELFI; score range 0-100). Analyses were by intention to treat. The trial is registered with ANZCTR.org.au, ACTRN12614000399695, and is completed. FINDINGS: Between Aug 18, 2014, and Sept 5, 2018, 154 participants were randomly assigned to integrated oncogeriatric care (n=76) or usual care (n=78). 13 participants died by week 12 and 130 (92%) of the remaining 141 participants completed two or more ELFI assessments. Participants assigned to integrated oncogeriatric care reported better adjusted ELFI change scores over 24 weeks compared with those in the usual care group (overall main effect of group: t=2·1, df=213, p=0·039; effect size=0·38), with maximal between-group differences at week 18 (mean difference in change 9·8 [95% CI 2·4-17·2]; p=0·010, corrected p=0·030, effect size=0·48). The integrated oncogeriatric care group also had significantly fewer unplanned hospital admissions at 24 weeks (multivariable-adjusted incidence rate ratio 0·60 [95% CI 0·42-0·87]; p=0·0066). No statistically significant between-group difference was observed in overall survival. INTERPRETATION: CGA led to better quality of life and health-care delivery in older people receiving systemic anticancer treatment. Routine CGA-based interventions should be considered in at-risk older people starting systemic anticancer treatment. FUNDING: National Health and Medical Research Council (Australia), Monash University, and Eastern Health.
引用
- Soo WK, King MT, Pope A, et al. Integrated Geriatric Assessment and Treatment Effectiveness (INTEGERATE) in older people with cancer starting systemic anticancer treatment in Australia: a multicentre, open-label, randomised controlled trial. Lancet Healthy Longev. 2022. PMID: 36102776. doi:10.1016/S2666-7568(22)00169-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。